Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.5.100NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.43.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EU.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.15.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.273NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.13 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.358NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22683US
B.1.177.60NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.159NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.510NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.91NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.227NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.555NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.513NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XACNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XZNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4.6.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBJNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EJ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
DQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.31.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.77NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.66NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GS.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.21.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EE.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
ES.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used